|
gptkbp:instanceOf
|
gptkb:antipsychotic_medication
|
|
gptkbp:approvalYear
|
1993
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05AX08
|
|
gptkbp:brand
|
gptkb:Risperdal_Consta
gptkb:Risperdal
|
|
gptkbp:CASNumber
|
106266-06-2
|
|
gptkbp:chemicalFormula
|
C23H27FN4O2
|
|
gptkbp:contraindication
|
hypersensitivity to risperidone
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:discoveredIn
|
1984
|
|
gptkbp:drugClass
|
benzisoxazole derivative
|
|
gptkbp:eliminationHalfLife
|
3-20 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:genericAvailable
|
true
|
|
gptkbp:interactsWith
|
gptkb:CNS_depressants
CYP2D6 inhibitors
antihypertensive drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1994
|
|
gptkbp:mechanismOfAction
|
dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:paliperidone
liver
|
|
gptkbp:patentExpired
|
2003
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
adults
children
elderly
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:riskFactor
|
neuroleptic malignant syndrome
tardive dyskinesia
stroke in elderly with dementia
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
anxiety
constipation
dizziness
weight gain
drowsiness
extrapyramidal symptoms
increased prolactin
|
|
gptkbp:synonym
|
gptkb:Risperdal_Consta
gptkb:Risperdal
|
|
gptkbp:usedFor
|
bipolar disorder
schizophrenia
irritability associated with autism
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Paul_Janssen
gptkb:Zyprexa
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
risperidone
|